Circulating Tumor Cells with ALK Rearrangement in ALK-positive NSCLC 

Get Permission

The diagnostic test for ALK rearrangement in non–small cell lung cancer (NSCLC) for crizotinib (Xalkori) treatment currently uses biopsy or fine-needle aspiration. Pailler and colleagues assessed whether ALK rearrangement could be detected using circulating tumor cells. They analyzed circulating tumor cells in 18 ALK-positive and 14 ALK-negative patients using a filtration enrichment technique and filter-adapted fluorescence in situ hybridization.

All ALK-positive patients had four or more ALK-rearranged circulating tumor cells per 1 mL of blood, whereas ALK-negative patients had no or one ALK-rearranged circulating tumor cell. ALK-rearranged circulating tumor cells harbored a unique (3’5’) split pattern, whereas tumors exhibited heterogeneous split patterns (3’5’, only 3’). The ALK-rearranged circulating tumor cells also expressed a mesenchymal phenotype, in contrast with the heterogeneous epithelial and mesenchymal marker expression observed in tumors. Variations in ALK-rearranged circulating tumor cell levels were detected in the five patients being treated with crizotinib.

The investigators wrote, “ALK rearrangement can be detected in [circulating tumor cells] of patients with ALK-positive NSCLC by using a filtration technique and [filter-adapted fluorescence in situ hybridization], enabling both diagnostic testing and monitoring of crizotinib treatment. Our results suggest that [circulating tumor cells] harboring a unique ALK rearrangement and mesenchymal phenotype may arise from clonal selection of tumor cells that have acquired the potential to drive metastatic progression of ALK-positive NSCLC.” ■

Pailler E, et al: J Clin Oncol. May 13, 2013 (early release online).




By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.